Accelerating R&D With AI/ML

Industry Challenges

Pharma, biotech and medtech organizations face rising R&D costs, long development cycles, and increasing regulatory complexity. Data is siloed across clinical, imaging, omics, real-world evidence and laboratory systems, limiting insight generation. While AI and machine learning (ML) show promise, many organizations struggle to operationalize it within regulated GxP environments.

Coforge’s Solution

Our solution provides a unified, GxP-compliant AI/ML workbench that accelerates discovery, clinical development and regulatory readiness. It integrates advanced analytics, generative AI and ML into a scalable cloud-native platform tailored for life sciences R&D.

How It Works

The platform ingests structured and unstructured data from clinical systems, imaging repositories, omics pipelines and external datasets. Data is normalized into a governed analytics environment that supports model development, validation and deployment. AI-powered capabilities enable target identification, trial optimization, imaging analytics, predictive safety and efficacy analysis and real-world evidence generation. Built-in compliance, auditability and quality engineering support regulatory submissions.

Business Impact

• Faster time-to-market

• Improved trial efficiency and reduced rework

• Increased R&D productivity

• Decreased compliance risks

• Reduced cost of innovation through reusable assets

• Improved scalability

Why This Matters

As competition intensifies, the ability to industrialize AI in R&D is critical. Our R&D acceleration solution transforms AI from isolated experimentation into a regulatory compliant core capability that drives innovation and scientific outcomes.